NCT02600169View on ClinicalTrials.gov

Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab

CompletedOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Melanoma
Interventions
DRUG

Pemprolizumab

All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.

Trial Locations (1)

9713 GZ

University Medical Center Groningen, Groningen

All Listed Sponsors
lead

University Medical Center Groningen

OTHER

NCT02600169 - Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab | Biotech Hunter | Biotech Hunter